The board of Boston-based biopharmaceutical company Vertex Pharmaceuticals (VRTX) has approved a $1.5 billion share repurchase program, per the company’s SEC filing.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported consolidated financial results for the quarter ended March 31, 2017. Vertex also reiterated guidance for total 2017 ORKAMBI® (lumacaftor/ivacaftor) revenues …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are up nearly 6% in pre-market trading Wednesday, after the drug maker laid out a development plan for …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple …
